Zhejiang Shouxiangu Pharm Co (603896) - Total Liabilities
Based on the latest financial reports, Zhejiang Shouxiangu Pharm Co (603896) has total liabilities worth CN¥927.41 Million CNY (≈ $135.71 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 603896 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Zhejiang Shouxiangu Pharm Co - Total Liabilities Trend (2012–2025)
This chart illustrates how Zhejiang Shouxiangu Pharm Co's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Zhejiang Shouxiangu Pharm Co balance sheet assets.
Zhejiang Shouxiangu Pharm Co Competitors by Total Liabilities
The table below lists competitors of Zhejiang Shouxiangu Pharm Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eik fasteignafélag hf
IC:EIK
|
Iceland | Ikr109.70 Billion |
|
HANSEN TECHNOLOGIES LTD.
F:H2T
|
Germany | €227.03 Million |
|
Magnera Corp placeholder
NYSE:MAGN
|
USA | $2.82 Billion |
|
SuZhou ChunXing Precision Mechanical Co Ltd
SHE:002547
|
China | CN¥4.65 Billion |
|
Electra Real Estate Ltd
TA:ELCRE
|
Israel | ILA580.77 Million |
|
Carlsmed, Inc.
NASDAQ:CARL
|
USA | $33.96 Million |
|
Codere Online US Corp
NASDAQ:CDRO
|
USA | $50.38 Million |
|
TIDEWATER RENEWABLES LTD
F:7GZ
|
Germany | €297.10 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Zhejiang Shouxiangu Pharm Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Zhejiang Shouxiangu Pharm Co to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Shouxiangu Pharm Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Shouxiangu Pharm Co (2012–2025)
The table below shows the annual total liabilities of Zhejiang Shouxiangu Pharm Co from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.02 Billion ≈ $149.42 Million |
+21.97% |
| 2024-12-31 | CN¥837.17 Million ≈ $122.50 Million |
-16.54% |
| 2023-12-31 | CN¥1.00 Billion ≈ $146.78 Million |
+5.51% |
| 2022-12-31 | CN¥950.67 Million ≈ $139.11 Million |
+177.64% |
| 2021-12-31 | CN¥342.41 Million ≈ $50.11 Million |
-8.27% |
| 2020-12-31 | CN¥373.28 Million ≈ $54.62 Million |
+121.77% |
| 2019-12-31 | CN¥168.31 Million ≈ $24.63 Million |
-18.61% |
| 2018-12-31 | CN¥206.79 Million ≈ $30.26 Million |
+265.38% |
| 2017-12-31 | CN¥56.60 Million ≈ $8.28 Million |
-67.69% |
| 2016-12-31 | CN¥175.17 Million ≈ $25.63 Million |
-26.21% |
| 2015-12-31 | CN¥237.38 Million ≈ $34.74 Million |
+31.56% |
| 2014-12-31 | CN¥180.43 Million ≈ $26.40 Million |
+64.24% |
| 2013-12-31 | CN¥109.85 Million ≈ $16.07 Million |
-19.01% |
| 2012-12-31 | CN¥135.64 Million ≈ $19.85 Million |
-- |
About Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the breeding, cultivation, processing, and sale of Chinese medicinal herbs in China and internationally. The company offers ganoderma lucidum spore powder, dendrobium officinale, and saffron products, as well as health and ordinary food, agricultural and sideline products, personal and skincare, and tradition… Read more